Stock Research for MNKD

MNKD
Current Price

$2.9900


Latest Update: 2018-02-16 16:00:00

High
$ 2.9900
Low
$ 2.9800
Close
$ 2.9900
Volume
158544
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

MNKD Stock Chart & Research Data

The MNKD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MNKD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


MNKD Due diligence Resources & Stock Charts

The MNKD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MNKD Detailed Price Forecast - CNN Money CNN View MNKD Detailed Summary - Google Finance
Yahoo View MNKD Detailed Summary - Yahoo! Finance Zacks View MNKD Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View MNKD Trends & Analysis - Trade-Ideas Barrons View MNKD Major Holders - Barrons
NASDAQ View MNKD Call Transcripts - NASDAQ Seeking View MNKD Breaking News & Analysis - Seeking Alpha
Spotlight View MNKD Annual Report - CompanySpotlight.com OTC Report View MNKD OTC Short Report - OTCShortReport.com
TradeKing View MNKD Fundamentals - TradeKing Charts View MNKD SEC Filings - Bar Chart
WSJ View Historical Prices for MNKD - The WSJ Morningstar View Performance/Total Return for MNKD - Morningstar
MarketWatch View the Analyst Estimates for MNKD - MarketWatch CNBC View the Earnings History for MNKD - CNBC
StockMarketWatch View the MNKD Earnings - StockMarketWatch MacroAxis View MNKD Buy or Sell Recommendations - MacroAxis
Bullish View the MNKD Bullish Patterns - American Bulls Short Pains View MNKD Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View MNKD Stock Mentions - StockTwits PennyStocks View MNKD Stock Mentions - PennyStockTweets
Twitter View MNKD Stock Mentions - Twitter Invest Hub View MNKD Investment Forum News - Investor Hub
Yahoo View MNKD Stock Mentions - Yahoo! Message Board Seeking Alpha View MNKD Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for MNKD - SECform4.com Insider Cow View Insider Transactions for MNKD - Insider Cow
CNBC View MNKD Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MNKD - OTC Markets
Yahoo View Insider Transactions for MNKD - Yahoo! Finance NASDAQ View Institutional Holdings for MNKD - NASDAQ


Stock Charts

FinViz View MNKD Stock Insight & Charts - FinViz.com StockCharts View MNKD Investment Charts - StockCharts.com
BarChart View MNKD Stock Overview & Charts - BarChart Trading View View MNKD User Generated Charts - Trading View


Latest Financial News for MNKD

Today’s Research Reports on Trending Tickers: Dare Bioscience and MannKind
Posted on Tuesday February 13, 2018

NEW YORK, NY / ACCESSWIRE / February 13, 2018 / U.S. markets rallied on Monday, after posting its worst weekly decline in two years, as President Trump unveiled details from his long awaited $200 billion ...


MannKind Corporation Appoints Dr. David Kendall as Chief Medical Officer
Posted on Tuesday February 06, 2018

MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes, today announced the appointment of David M. Kendall, MD, as Chief Medical Officer, effective February 12. Dr. Kendall will assume full responsibility for leading MannKind's scientific research, clinical development, regulatory, and medical affairs activity.


David Kendall Joins MannKind as Chief Medical Officer
Posted on Tuesday February 06, 2018

WESTLAKE VILLAGE, Calif., Feb. 06, 2018-- MannKind Corporation today announced that David M. Kendall, MD, will join the company as Chief Medical Officer and assume full responsibility for leading MannKind’ ...


Here's Why MannKind Briefly Spiked Today
Posted on Monday January 29, 2018

The volatility continues.


MannKind - Afrezza Scripts Remain Underwhelming As Quarter Reaches Halfway Point
Seeking Alpha - Feb 17, 2018
Another week in 2018 has passed and MannKind (NASDAQ:MNKD) investors see another week where the sales of Afrezza are underwhelming.

MannKind: Adios, Arrivederci, Ciao, Au Revoir, Bon Voyage, Sayonara
Seeking Alpha - Feb 13, 2018
With the beginning of the 3rd quarter of 2016, MannKind relaunched Afrezza into the marketplace under MannKind's direct leadership and with an active sales force in the field. With data now available for the ensuing 83 weeks under MannKind's marketing ...

Don't Buy MannKind Corporation Stock Under Any Circumstances
Investorplace.com - Feb 12, 2018
Stocks that lose more than 90% of their value have an uphill climb to earn investors' trust again. Sometimes that climb can take years.
Analysts Are Largely Bullish Or Bearish On MBIA Inc. (MBI), MannKind ... - Post Analyst
MannKind Corporation (MNKD) Stock Price Increases Today - BZ Weekly

Why MannKind Corporation Stock Is Falling Back to Earth Today
Motley Fool - Jan 26, 2018
With the sales of its inhaled insulin product, Afrezza, failing to pick up in a financially meaningful way after a favorable label change last year, MannKind appears to be a dead man walking at this point. To stave off bankruptcy, the company really ...
Is MannKind Corporation Stock Really Worth the Risk? - Investorplace.com
MannKind Corporation (MNKD) Soars 7.6% on January 24 - Equities.com

Enter a stock symbol to view the stock details.